Clinical trials: Proton Pump Inhibitors
Heartburn
Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)
This study will evaluate a single ingredient product (omeprazole 20 mg) with a combination product capsule (omeprazole 20 mg + sodium bicarbonate 1100 mg) in participants with frequent heartburn.
- Trial name
- NCT01587885
- Testing
- Omeprazole 20 mg + Sodium Bicarbonate 1100 mg, Omeprazole 20 mg
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Participants
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants.
- Trial name
- NCT07643272
- Testing
- HMPL-760, Rabeprazole and HMPL-760
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Healthy Participants
A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
The main aim of this study to compare the pharmacokinetics (PK) of two formulations of AZD4144 and assess the effect of food and omeprazole on PK of AZD4144 in healthy participants.
- Trial name
- NCT06948006
- Testing
- AZD4144, Omeprazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.
This is an open-label, randomized, cross-over, single dose study in healthy volunteers to evaluate the potential effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of crizotinib.
- Trial name
- NCT01549574
- Testing
- crizotinib, esomeprazole
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to…
- Trial name
- NCT00942136
- Testing
- GSK1349572, Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
This is a Phase 1, open-label, randomized, four-period, crossover study in healthy females of nonchildbearing potential and male subjects - to be conducted at a single center in the United States.
- Trial name
- NCT04211545
- Testing
- Rabeprazole, CC-92480
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
GERD
A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
Background: Gastroesophageal reflux disease (GERD), which affects at least 20% of adult Americans, may be especially common and severe in Veteran patients.
- Trial name
- NCT01265550
- Testing
- Nissen fundoplication, baclofen, Desipramine
- Where
- 15 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Heartburn
Symptom Control Satisfaction With Proton Pump Inhibitor Regimen
The overall aim of this study is to assess if patients with persistent gastroesophageal reflux disease (GERD) symptoms receiving sub-optimal omeprazole dosing experience improvement in GERD symptoms when prescribed an optimal…
- Trial name
- NCT02623816
- Testing
- Optimal Dosing of Omeprazole
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- MetroHealth Medical Center
Healthy
Surufatinib DDI With a PPI and a CYP3A Inducer
The purpose of this is to evaluate the effect of proton pump inhibitor (rabeprazole) and the effect of a CYP3A inducer (rifampin) on the pharmacokinetics of Surufatinib.
- Trial name
- NCT04510649
- Testing
- Part A, Part B
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
Drug Interaction, Food-drug Interaction
Fruquintinib Food Effect and Proton Pump Inhibitor Study
The purpose of this is to evaluate the effect of food and the effect of a proton pump inhibitor (rabeprazole) on the pharmacokinetics of fruquintinib.
- Trial name
- NCT04645940
- Testing
- fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
Healthy Volunteer
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) [rabeprazole] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants.
- Trial name
- NCT06264440
- Testing
- BIIB122, Rabeprazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Biogen
Hypovitaminosis b 12
This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcting Early-onset Vitamin B12 Deficiency in Adult Patients Using Proton Pump Inhibitors (PPIs). The Primary Outcome is the Change in Serum Vitamin B12 Levels Over a 6-week
This randomized, clinical trial evaluates the efficacy of oral versus sublingual vitamin B12 supplementation in correcting early-onset vitamin B12 deficiency in adult patients using proton pump inhibitors (PPIs).
- Trial name
- NCT06966856
- Testing
- Cyanocobalamin 1000 Mcg Oral Tablet, Cyanocobalamin 1000 Mcg Sublingual Tablet, Proton Pump Inhibitor therapy only
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tanta University
Healthy
Effect of Inhibitors of the Proton Pump on Intestinal Transporters
Dabigatran etexilate is a novel oral anticoagulant. It is indicated in venous thromboembolic prevention in orthopedic surgery and has recently shown greater efficiency and tolerance as anticoagulants in preventing thromboembolism…
- Trial name
- BIPP (NCT02524210)
- Testing
- Dabigatran, Rabeprazole and Dabigatran, Omeprazole and Dabigatran
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Osteoporosis, Hypomagnesemia
Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn.
- Trial name
- NCT03812380
- Testing
- EffCaMgCit
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Gastroesophageal Reflux Disease (GERD)
The EndoGastric Solutions TEMPO Trial
The purpose of this study is to assess the efficacy and safety of Transoral Incisionless Fundoplication (TIF) performed with EsophyX as compared to proton pump inhibitor (PPI) therapy for the treatment of chronic Gastroesophageal…
- Trial name
- TEMPO (NCT01647958)
- Testing
- EsophyX System with SerosaFuse fasteners, PPI
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- EndoGastric Solutions
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Healthy
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.
This study will estimate the effect of food and the proton pump inhibitor, esomeprazole on the pharmacokinetics of crizotinib in a coated microsphere formulation.
- Trial name
- NCT03137134
- Testing
- Crizotinib, Esomeprazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Helicobacter Pylori Infection
The Role of Probiotics in the Eradication of Helicobacter Pylori
All patients will receive quadruple eradication therapy for 10 days with Omerazole 20mg x2, Amoxicilin 1g x2, Clarithromycin 500mg x2 and Metronidazole 500mg x2. The patients will be randomised into two groups.
- Trial name
- NCT04178187
- Testing
- Caps Lactolevure
- Where
- 5 sites in Greece
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Evangelismos Hospital
Healthy
Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)
Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole.
- Trial name
- NCT01918176
- Testing
- Palbociclib alone, Palbociclib + Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nutritional Status
Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors
GSK1325756 is a potent, competitive, selective and reversible CXCR2 receptor antagonist that is being developed as a once-daily oral anti-inflammatory medication for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01209104
- Testing
- GSK1325756
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline